MEDICUS PHARMA RECEIVES FDA “STUDY MAY PROCEED” LETTER FOR NDA-ENABLING REGISTRATIONAL SKINJECT® STUDY IN PATIENTS WITH GORLIN SYNDROME

Reuters · 2d ago

Please log in to view news